|
Title
|
109493: A double Blind, Randomized, Placebo controlled phase III study to Assess the efficacy of recMAGE-A3 + AS15 Antigen specific cancer immunotherapeutic as adjuvant therapy in patients with resectable MAGE-A3 positive NSCLC
|
|
Protocol Number
|
GSK1572932A
|
|
Study Contact
|
|
|
Principal Investigator
|
|
|
Rationale
|
Primary objective is to demonstrate the clinical efficacy to recMAGE-A3 + AS15 versus placebo in NSCLC after complete resection. Secondary objective is to consider the efficacy in the population of patients who did not receive
|
|
Available at:
|
Clinical Cancer Center
GCRC
Tisch
|
|
Intervention Type
|
Therapeutic
|
|
Age Requirement
|
older than 18 years
|
|
Gender
|
males and females
|
|
Healthy Subjects?
|
no
|
|
Eligibility Criteria
|
Please refer to attached study protocol below
|
|
URL
|
http://www.med.nyu.edu/nyuci/
|
